Expanding the Role of Radium-223 (Xofigo)

One of the newer drugs and one that has recently had great air play is the bone targeting radiopharmaceutical drug radium-223 or Xofigo. Currently, it is approved for men with castrate resistant prostate cancer with bone metastases. The problem is that currently Xofigo is only approved for one round of treatment using 6 monthly infusions. Given its success, the question we are now asking is if additional dosing would provide an even better result? Bayer Pharmaceuticals currently has a number of clinical trials examining this type of question. In one of the small prospective studies looking at the impact of [...]

A Brief Update of the Current Landscape of Bone Targeted Therapies for Prostate Cancer

Prostate cancer tends to metastasize to bones as opposed to soft tissue and other organs.   We have no idea why it does have a preference for bone, but it does. Developing bone metastases in prostrate cancer is a very strong negative prognostic indicator. Prostate cancer’s tendency to favor bone over soft tissue causes significant morbidity and mortality for men. Bone metastasis has a major impact on quality of life and longevity for men with prostate cancer and it needs to be aggressively treated. Because of this, prostate cancer survivors need to focus on drugs that slow down or interfere with [...]

Belfast Clinical Trial Combining Two Radio-Therapies For Men With Advanced Prostate Cancer

Researchers at Queen’s University in Belfast along with the Belfast Trust are conducting a clinical trial evaluating the combination of two radiotherapy treatments, Radium 223 and Pelvic Radiation using Volumetric Modulated Arc Therapy (VMAT) in men with bone positive advanced prostate cancer. The trial, being called ADRRAD trial, involves combining androgen deprivation therapy (ADT) along with the two radio-therapies. Treatment is expected to last about 18 months. VMAT is an externally delivered type of radiotherapy that manipulates radiation beams to adapt to the shape of the tumor, delivering a more precise dose of radiation and limiting damage to surrounding tissue. Radium 223 is [...]

Repeating Treatment with Radium-223 (Xofigo) is Safe and Effective

Radium-223 (Xofigo) is a drug for men with castrate resistant metastatic prostate cancer (mCRCP) who have multiple bone metastases. Radium-223 selectively targets bone metastases by mimicking calcium, which is attracted to the bone, especially to the fast growing areas of the tumor in the bone. It emits an alpha-emitting dose of radiation, which is mostly contained in the tumor due to the low spread of alpha waves). The current FDA approval for Radium-223 is for one course of 6 injections. Men have been asking if it is possible to have a re-treatment of Radium-223 once the disease has progressed after having [...]